Cargando…

Treatment for a B-cell acute lymphoblastic leukemia patient carrying a rare TP53 c.C275T mutation: A case report

TP53 mutations are associated with poor prognosis in the vast majority of cancers. In this study, we present a pediatric B-cell acute lymphoblastic leukemia (B-ALL) patient carrying a rare TP53 c.C275T mutation. This extremely rare mutation affects an amino acid residue located between the TAD domai...

Descripción completa

Detalles Bibliográficos
Autores principales: Wang, Runan, Wang, Wenliang, Liu, Xuan, Wang, Huan, Zhang, Bin, Li, Shuang, Zhang, Haining, Yang, Jiawei, Zhao, Jishun, He, Qiuying, Zhang, Jihong, Liu, Danping, Hao, Liangchun
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9928200/
https://www.ncbi.nlm.nih.gov/pubmed/36798689
http://dx.doi.org/10.3389/fonc.2022.1018250
_version_ 1784888602814054400
author Wang, Runan
Wang, Wenliang
Liu, Xuan
Wang, Huan
Zhang, Bin
Li, Shuang
Zhang, Haining
Yang, Jiawei
Zhao, Jishun
He, Qiuying
Zhang, Jihong
Liu, Danping
Hao, Liangchun
author_facet Wang, Runan
Wang, Wenliang
Liu, Xuan
Wang, Huan
Zhang, Bin
Li, Shuang
Zhang, Haining
Yang, Jiawei
Zhao, Jishun
He, Qiuying
Zhang, Jihong
Liu, Danping
Hao, Liangchun
author_sort Wang, Runan
collection PubMed
description TP53 mutations are associated with poor prognosis in the vast majority of cancers. In this study, we present a pediatric B-cell acute lymphoblastic leukemia (B-ALL) patient carrying a rare TP53 c.C275T mutation. This extremely rare mutation affects an amino acid residue located between the TAD domain and the DNA-binding domain of p53. The patient was resistant to most conventional chemotherapy regimens and remained minimal residual disease (MRD)-positive after five rounds of such regimens. We tested the sensitivity of the patient’s leukemic cells to 21 anti-cancer drugs by performing in vitro drug sensitivity assays. The results showed that bortezomib had a very strong killing effect on the patient’s leukemic cells. Therefore, we subsequently treated the patient with bortezomib combined with vindesine, cytarabine, and fludarabine. After one course of treatment, the patient became MRD-negative, and there was no recurrence during a 9-month follow-up. In conclusion, our report suggests that the TP53 c.C275T mutation is associated with poor prognosis in B-ALL. Fortunately, bortezomib combined with chemotherapy could achieve a better therapeutic effect than conventional regimens in this type of ALL.
format Online
Article
Text
id pubmed-9928200
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-99282002023-02-15 Treatment for a B-cell acute lymphoblastic leukemia patient carrying a rare TP53 c.C275T mutation: A case report Wang, Runan Wang, Wenliang Liu, Xuan Wang, Huan Zhang, Bin Li, Shuang Zhang, Haining Yang, Jiawei Zhao, Jishun He, Qiuying Zhang, Jihong Liu, Danping Hao, Liangchun Front Oncol Oncology TP53 mutations are associated with poor prognosis in the vast majority of cancers. In this study, we present a pediatric B-cell acute lymphoblastic leukemia (B-ALL) patient carrying a rare TP53 c.C275T mutation. This extremely rare mutation affects an amino acid residue located between the TAD domain and the DNA-binding domain of p53. The patient was resistant to most conventional chemotherapy regimens and remained minimal residual disease (MRD)-positive after five rounds of such regimens. We tested the sensitivity of the patient’s leukemic cells to 21 anti-cancer drugs by performing in vitro drug sensitivity assays. The results showed that bortezomib had a very strong killing effect on the patient’s leukemic cells. Therefore, we subsequently treated the patient with bortezomib combined with vindesine, cytarabine, and fludarabine. After one course of treatment, the patient became MRD-negative, and there was no recurrence during a 9-month follow-up. In conclusion, our report suggests that the TP53 c.C275T mutation is associated with poor prognosis in B-ALL. Fortunately, bortezomib combined with chemotherapy could achieve a better therapeutic effect than conventional regimens in this type of ALL. Frontiers Media S.A. 2023-01-31 /pmc/articles/PMC9928200/ /pubmed/36798689 http://dx.doi.org/10.3389/fonc.2022.1018250 Text en Copyright © 2023 Wang, Wang, Liu, Wang, Zhang, Li, Zhang, Yang, Zhao, He, Zhang, Liu and Hao https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Oncology
Wang, Runan
Wang, Wenliang
Liu, Xuan
Wang, Huan
Zhang, Bin
Li, Shuang
Zhang, Haining
Yang, Jiawei
Zhao, Jishun
He, Qiuying
Zhang, Jihong
Liu, Danping
Hao, Liangchun
Treatment for a B-cell acute lymphoblastic leukemia patient carrying a rare TP53 c.C275T mutation: A case report
title Treatment for a B-cell acute lymphoblastic leukemia patient carrying a rare TP53 c.C275T mutation: A case report
title_full Treatment for a B-cell acute lymphoblastic leukemia patient carrying a rare TP53 c.C275T mutation: A case report
title_fullStr Treatment for a B-cell acute lymphoblastic leukemia patient carrying a rare TP53 c.C275T mutation: A case report
title_full_unstemmed Treatment for a B-cell acute lymphoblastic leukemia patient carrying a rare TP53 c.C275T mutation: A case report
title_short Treatment for a B-cell acute lymphoblastic leukemia patient carrying a rare TP53 c.C275T mutation: A case report
title_sort treatment for a b-cell acute lymphoblastic leukemia patient carrying a rare tp53 c.c275t mutation: a case report
topic Oncology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9928200/
https://www.ncbi.nlm.nih.gov/pubmed/36798689
http://dx.doi.org/10.3389/fonc.2022.1018250
work_keys_str_mv AT wangrunan treatmentforabcellacutelymphoblasticleukemiapatientcarryingararetp53cc275tmutationacasereport
AT wangwenliang treatmentforabcellacutelymphoblasticleukemiapatientcarryingararetp53cc275tmutationacasereport
AT liuxuan treatmentforabcellacutelymphoblasticleukemiapatientcarryingararetp53cc275tmutationacasereport
AT wanghuan treatmentforabcellacutelymphoblasticleukemiapatientcarryingararetp53cc275tmutationacasereport
AT zhangbin treatmentforabcellacutelymphoblasticleukemiapatientcarryingararetp53cc275tmutationacasereport
AT lishuang treatmentforabcellacutelymphoblasticleukemiapatientcarryingararetp53cc275tmutationacasereport
AT zhanghaining treatmentforabcellacutelymphoblasticleukemiapatientcarryingararetp53cc275tmutationacasereport
AT yangjiawei treatmentforabcellacutelymphoblasticleukemiapatientcarryingararetp53cc275tmutationacasereport
AT zhaojishun treatmentforabcellacutelymphoblasticleukemiapatientcarryingararetp53cc275tmutationacasereport
AT heqiuying treatmentforabcellacutelymphoblasticleukemiapatientcarryingararetp53cc275tmutationacasereport
AT zhangjihong treatmentforabcellacutelymphoblasticleukemiapatientcarryingararetp53cc275tmutationacasereport
AT liudanping treatmentforabcellacutelymphoblasticleukemiapatientcarryingararetp53cc275tmutationacasereport
AT haoliangchun treatmentforabcellacutelymphoblasticleukemiapatientcarryingararetp53cc275tmutationacasereport